The tissue factor-TFPI pathway as a therapeutic target in bleeding disorders of unknown cause
Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 3874-3883
DOI: 10.1016/j.jtha.2026.08.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Elena Monzón Manzano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-IdiPAZ, Madrid, Spain. Hauptthemen laut MEDLINE: Thromboplastin, Lipoproteins, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk A/S, ISCIII.
Abstract (Originalsprache)
BACKGROUND: Bleeding disorders of unknown cause (BDUC) comprise a heterogeneous group of conditions characterized by clinically significant bleeding despite normal results on standard hemostatic investigations. OBJECTIVES: To investigate tissue factor (TF)-dependent coagulation in patients with BDUC and to evaluate the in vitro ability of concizumab and recombinant activated factor VII (rFVIIa) to restore thrombin generation. METHODS: Thrombin generation was assessed using an assay designed to isolate TF-dependent coagulation by inhibiting contact pathway activation with corn trypsin inhibitor. Tissue factor pathway inhibitor (TFPI) activity was measured. RESULTS: A subgroup of patients with BDUC exhibited impaired thrombin generation under these conditions. Reduced thrombin generation was frequently associated with increased TFPI activity, suggesting that excessive inhibition of TF-mediated coagulation contributes to the bleeding phenotype in a subset of patients. In vitro addition of concizumab or rFVIIa restored thrombin generation, indicating that defects in TF-dependent coagulation can be pharmacologically corrected. CONCLUSION: These findings identify dysregulation of the TF-TFPI axis as a potential pathophysiological mechanism underlying bleeding in a subset of patients with BDUC and highlight TFPI inhibition and rFVIIa administration as potential therapeutic approaches. However, the absence of abnormalities in all patients supports the concept that BDUC represents a biologically heterogeneous group of disorders with multiple underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-IdiPAZ, Madrid, Spain.
- Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-IdiPAZ, Madrid, Spain; Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain.
- Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-IdiPAZ, Madrid, Spain. Electronic address: nora.butta@salud.madrid.org.
Förderung
- Novo Nordisk A/S
- ISCIII
Zitieren
APA
Monzón Manzano, E., Acuña, P., Martín Salces, M., Rivas Pollmar, M. I., García Pérez, E., Martín de Bustamante González-Iglesias, J. M., Gutiérrez, M., Jiménez Yuste, V., Butta, N., & Álvarez Román, M. T. (2026). The tissue factor-TFPI pathway as a therapeutic target in bleeding disorders of unknown cause. Journal of Thrombosis and Haemostasis, 24(11), 3874-3883. https://doi.org/10.1016/j.jtha.2026.08.016
Vancouver
Monzón Manzano E, Acuña P, Martín Salces M, Rivas Pollmar MI, García Pérez E, Martín de Bustamante González-Iglesias JM, et al. The tissue factor-TFPI pathway as a therapeutic target in bleeding disorders of unknown cause. Journal of Thrombosis and Haemostasis. 2026;24(11):3874-3883. doi:10.1016/j.jtha.2026.08.016
BibTeX
@article{MonznManzano2026,
author = {Monzón Manzano, Elena and Acuña, Paula and Martín Salces, Mónica and Rivas Pollmar, María Isabel and García Pérez, Eduardo and Martín de Bustamante González-Iglesias, José Manuel and Gutiérrez, Mar and Jiménez Yuste, Víctor and Butta, Nora and Álvarez Román, María Teresa},
title = {The tissue factor-TFPI pathway as a therapeutic target in bleeding disorders of unknown cause},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {11},
pages = {3874--3883},
doi = {10.1016/j.jtha.2026.08.016}
}
EUVIMED